View Item 

Show simple item record

A multi‐institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer
dc.contributor.authorKim, Edward J.en_US
dc.contributor.authorBen‐josef, Edgaren_US
dc.contributor.authorHerman, Joseph M.en_US
dc.contributor.authorBekaii‐saab, Taniosen_US
dc.contributor.authorDawson, Laura A.en_US
dc.contributor.authorGriffith, Kent A.en_US
dc.contributor.authorFrancis, Isaac R.en_US
dc.contributor.authorGreenson, Joel K.en_US
dc.contributor.authorSimeone, Diane M.en_US
dc.contributor.authorLawrence, Theodore S.en_US
dc.contributor.authorLaheru, Danielen_US
dc.contributor.authorWolfgang, Christopher L.en_US
dc.contributor.authorWilliams, Terenceen_US
dc.contributor.authorBloomston, Marken_US
dc.contributor.authorMoore, Malcolm J.en_US
dc.contributor.authorWei, Aliceen_US
dc.contributor.authorZalupski, Mark M.en_US
dc.date.accessioned2013-08-02T20:51:50Z
dc.date.available2014-10-06T19:17:44Zen_US
dc.date.issued2013-08-01en_US
dc.identifier.citationKim, Edward J.; Ben‐josef, Edgar ; Herman, Joseph M.; Bekaii‐saab, Tanios ; Dawson, Laura A.; Griffith, Kent A.; Francis, Isaac R.; Greenson, Joel K.; Simeone, Diane M.; Lawrence, Theodore S.; Laheru, Daniel; Wolfgang, Christopher L.; Williams, Terence; Bloomston, Mark; Moore, Malcolm J.; Wei, Alice; Zalupski, Mark M. (2013). "A multiâ institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer." Cancer 119(15): 2692-2700. <http://hdl.handle.net/2027.42/99090>en_US
dc.identifier.issn0008-543Xen_US
dc.identifier.issn1097-0142en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/99090
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherPancreatic Canceren_US
dc.subject.otherNeoadjuvanten_US
dc.subject.otherGemcitabineen_US
dc.subject.otherOxaliplatinen_US
dc.titleA multi‐institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic canceren_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbsecondlevelPublic Healthen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.identifier.pmid23720019en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/99090/1/cncr28117.pdf
dc.identifier.doi10.1002/cncr.28117en_US
dc.identifier.sourceCanceren_US
dc.identifier.citedreferenceLoehrer PJ Sr, Feng Y, Cardenes H, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2011; 29: 4105 – 4112.en_US
dc.identifier.citedreferenceSiegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62: 10 – 29.en_US
dc.identifier.citedreferenceNeoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010; 304: 1073 – 1081.en_US
dc.identifier.citedreferenceOettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative‐intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007; 297: 267 – 277.en_US
dc.identifier.citedreferenceRegine WF, Winter KA, Abrams RA, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil‐based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. 2008; 299: 1019 – 1026.en_US
dc.identifier.citedreferenceSperti C, Pasquali C, Piccoli A, Pedrazzoli S. Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg. 1997; 21: 195 – 200.en_US
dc.identifier.citedreferenceFuhrman GM, Charnsangavej C, Abbruzzese JL, et al. Thin‐section contrast‐enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms. Am J Surg. 1994; 167: 104 – 111; discussion 111‐103.en_US
dc.identifier.citedreferencePingpank JF, Hoffman JP, Ross EA, et al. Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J Gastrointest Surg. 2001; 5: 121 – 130.en_US
dc.identifier.citedreferenceLaurence JM, Tran PD, Morarji K, Eslick GD, Lam VW, Sandroussi C. A systematic review and meta‐analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer. J Gastrointest Surg. 2011; 15: 2059 – 2069.en_US
dc.identifier.citedreferenceEvans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine‐based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008; 26: 3496 – 3502.en_US
dc.identifier.citedreferenceVaradhachary GR, Wolff RA, Crane CH, et al. Preoperative gemcitabine and cisplatin followed by gemcitabine‐based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008; 26: 3487 – 3495.en_US
dc.identifier.citedreferenceDesai SP, Ben‐Josef E, Normolle DP, et al. Phase I study of oxaliplatin, full‐dose gemcitabine, and concurrent radiation therapy in pancreatic cancer. J Clin Oncol. 2007; 25: 4587 – 4592.en_US
dc.identifier.citedreferenceLawrence TS, Chang EY, Hahn TM, Hertel LW, Shewach DS. Radiosensitization of pancreatic cancer cells by 2′,2′‐difluoro‐2′‐deoxycytidine. Int J Radiat Oncol Biol Phys. 1996; 34: 867 – 872.en_US
dc.identifier.citedreferenceMcGinn CJ, Zalupski MM, Shureiqi I, et al. Phase I trial of radiation dose escalation with concurrent weekly full‐dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2001; 19: 4202 – 4208.en_US
dc.identifier.citedreferenceLouvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005; 23: 3509 – 3516.en_US
dc.identifier.citedreferenceMorgan MA, Meirovitz A, Davis MA, Kollar LE, Hassan MC, Lawrence TS. Radiotherapy combined with gemcitabine and oxaliplatin in pancreatic cancer cells. Transl Oncol. 2008; 1: 36 – 43.en_US
dc.identifier.citedreferenceTherasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205 – 216.en_US
dc.identifier.citedreferenceEvans DB, Rich TA, Byrd DR, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992; 127: 1335 – 1339.en_US
dc.identifier.citedreferenceMuler JH, McGinn CJ, Normolle D, et al. Phase I trial using a time‐to‐event continual reassessment strategy for dose escalation of cisplatin combined with gemcitabine and radiation therapy in pancreatic cancer. J Clin Oncol. 2004; 22: 238 – 243.en_US
dc.identifier.citedreferenceSmall W Jr, Berlin J, Freedman GM, et al. Full‐dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol. 2008; 26: 942 – 947.en_US
dc.identifier.citedreferenceTalamonti MS, Small W, Jr, Mulcahy MF, et al. A multi‐institutional phase II trial of preoperative full‐dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol. 2006; 13: 150 – 158.en_US
dc.identifier.citedreferenceBlackstock AW, Tepper JE, Niedwiecki D, Hollis DR, Mayer RJ, Tempero MA. Cancer and Leukemia Group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. Int J Gastrointest Cancer. 2003; 34: 107 – 116.en_US
dc.identifier.citedreferenceKatz MH, Pisters PW, Evans DB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg. 2008; 206: 833 – 846; discussion 846‐838.en_US
dc.identifier.citedreferencePatel M, Hoffe S, Malafa M, et al. Neoadjuvant GTX chemotherapy and IMRT‐based chemoradiation for borderline resectable pancreatic cancer. J Surg Oncol. 2011; 104: 155 – 161.en_US
dc.identifier.citedreferenceStokes JB, Nolan NJ, Stelow EB, et al. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. Ann Surg. Oncol. 2011; 18: 619 – 627.en_US
dc.identifier.citedreferenceCallery MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L, Linehan DC. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol. 2009; 16: 1727 – 1733.en_US
dc.identifier.citedreferenceDonahue TR, Isacoff WH, Hines OJ, et al. Downstaging chemotherapy and alteration in the classic computed tomography/magnetic resonance imaging signs of vascular involvement in patients with pancreaticobiliary malignant tumors: influence on patient selection for surgery. Arch Surg. 2011; 146: 836 – 843.en_US
dc.identifier.citedreferenceKatz MH, Fleming JB, Bhosale P, et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012; 118: 5749 – 5756.en_US
dc.identifier.citedreferenceConroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364: 1817 – 1825.en_US
dc.identifier.citedreferenceSultana A, Smith CT, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P. Meta‐analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol. 2007; 25: 2607 – 2615.en_US
dc.identifier.citedreferenceAssifi MM, Lu X, Eibl G, Reber HA, Li G, Hines OJ. Neoadjuvant therapy in pancreatic adenocarcinoma: a meta‐analysis of phase II trials. Surgery. 2011; 150: 466 – 473.en_US
dc.identifier.citedreferenceBen‐Josef E, Schipper M, Francis IR, et al. A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed‐dose rate gemcitabine (FDR‐G) in patients with unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2012; 84: 1166 – 1171.en_US
dc.identifier.citedreferenceVaradhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006; 13: 1035 – 1046.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncr28117.pdf
Size:
315.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.